Breaking down Barriers to
Precision Medicine

Expanding the reach of precision medicine by providing unprecedented resolution into disease-defining biology from a blood test.

ABOUT US

Unlocking the biology of disease
from a simple blood test.

We’ve developed a platform that uncovers the activation status of therapeutically actionable genes and pathways from a simple blood test. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

OUR SCIENCE

First-in-class epigenomic liquid biopsy

Our first-in-class liquid biopsy platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma. This genome-wide, feature-rich space of ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands gives us resolution into the dynamic activation of individual genes and pathways.

It starts in the clinic with a simple blood draw

We profile transcriptional biology using sophisticated molecular techniques

And apply proprietary machine learning approaches

To give you interpretable and actionable readouts

Expanding the universe
of precision medicine

OUR TEAM

Experts in liquid biopsy development,
computational biology & epigenomics

Jessica Alfano, Esq.

Vice President, Head of Legal

J. Carl Barrett, PhD

Chief Scientific Officer

Kristian Cibulskis

VP, Head of Bioinformatics Engineering

Travis Clark, PhD

Vice President, Product Development

Kristy Cobill

Head of Operations

Matthew Eaton, PhD

VP, Data Science

Jennifer Fortune, PhD

Senior Director

Humphrey Gardner, MD

Chief Medical Officer

Daniel H. Farkas, PhD

Director, Clinical Affairs

Josephine N. Harada, MBA, PhD

SVP, Business Development

Adrian Li, PhD

Director, Computational Biology

Geoff Otto, PhD

Chief Executive Officer

Rehan Verjee

President & COO

Christine Vietz, PhD

VP, Technical & Commercial Operations

SCIENTIFIC ADVISORY BOARD

Sylvan Baca, MD, PhD
Toni Choueiri, MD
Matthew Freedman, MD
Richard B. Lanman, MD
Doron Lipson, PhD
Joseph Loscalzo, MD, PhD
Daniel Marshak, PhD
Olga Troyanskaya, PhD

BOARD OF DIRECTORS

Wouter Meuleman, PhD
Alex Parker, PhD
Kush Parmar, MD, PhD
Rehan Verjee
Richard Young, PhD

PARTNER WITH US

Collaborating to advance
precision medicine

We are actively working with developers of new medicines to elucidate the biology behind treatment response and resistance and to identify new targets that are mechanistically linked to disease.

If you think our platform could make a difference to your medicine in development or your research problem, get in touch with us.

JOIN US

Build the future of
precision medicine with us

At Precede Biosciences, we believe hard problems are best solved by mission-driven colleagues who trust and genuinely care about one another. We also believe that every person on the team is essential to our success and that every one of us has the potential to change the fabric of the company, and the world, for the better.

If this resonates, and you think you can contribute, then apply to an open position.